Details for New Drug Application (NDA): 062655
✉ Email this page to a colleague
NDA 062655 describes TAZIDIME, which is a drug marketed by Lilly and is included in two NDAs. Additional details are available on the TAZIDIME profile page.
The generic ingredient in TAZIDIME is ceftazidime. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
The generic ingredient in TAZIDIME is ceftazidime. There are seventeen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ceftazidime profile page.
Summary for 062655
| Tradename: | TAZIDIME |
| Applicant: | Lilly |
| Ingredient: | ceftazidime |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 062655
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 1GM/VIAL | ||||
| Approval Date: | Nov 20, 1985 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 2GM/VIAL | ||||
| Approval Date: | Nov 20, 1985 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
